Antisera Against Certain Conserved Surface-Exposed Peptides of Nontypeable Haemophilus influenzae Are Protective

Paul W. Whitby1*, Thomas W. Seale1*, Daniel J. Morton1*, Terrence L. Stull1,2

1 Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America, 2 Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America

* These authors contributed equally to this work.
* pwhitby@ouhsc.edu

Abstract

Nontypeable Haemophilus influenzae (NTHi) cause significant disease, including otitis media in children, exacerbations of chronic obstructive pulmonary disease, and invasive disease in susceptible populations. No vaccine is currently available to prevent NTHi disease. The interactions of NTHi and the human host are primarily mediated by lipooligosaccharide and a complex array of surface-exposed proteins (SEPs) that act as receptors, sensors and secretion systems. We hypothesized that certain SEPs are present in all NTHi strains and that a subset of these may be antibody accessible and represent protective epitopes. Initially we used 15 genomic sequences available in the GenBank database along with an additional 11 genomic sequences generated by ourselves to identify the core set of putative SEPs present in all strains. Using bioinformatics, 56 core SEPs were identified. Molecular modeling generated putative structures of the SEPs from which potential surface exposed regions were defined. Synthetic peptides corresponding to ten of these highly conserved surface-exposed regions were used to raise antisera in rats. These antisera were used to assess passive protection in the infant rat model of invasive NTHi infection. Five of the antisera were protective, thus demonstrating their in vivo antibody accessibility. These five peptide regions represent potential targets for peptide vaccine candidates to protect against NTHi infection.

Introduction

Nontypeable Haemophilus influenzae (NTHi) cause both invasive and noninvasive infections, including otitis media, bacteremia and exacerbations of chronic obstructive pulmonary disease [1–4] and are a significant public health burden. The most common infection caused by NTHi is acute otitis media (AOM). AOM accounts for 33% of visits by children to health care centers and is the most frequent reason children receive antibiotics [5]. The incidence of AOM peaks between 6 and 12 months of life; almost 100% of children in developing communities and two-thirds of children in developed communities experience their first episode of OM by one year of age [6]. By age 3 years, 80% of children in the U.S. have experienced at least one episode, and
40% have three or more recurrent episodes [7]. Compared to children without AOM those with acute AOM had 2 additional office visits, 0.2 additional emergency room visits and 1.6 additional prescriptions per year. These visits lead to an estimated incremental increase in outpatient healthcare costs of $314 per year per child [8].

Historically, *Streptococcus pneumoniae* were the most common AOM isolate, and NTHi were the second most common [5]. Since the introduction of the PCV-7 *S. pneumoniae* vaccine in 2000, the number of cases of OM attributable to *S. pneumoniae* has markedly decreased [5,9]. However, the overall number of cases of OM has been reduced about 7% with the PCV-7 vaccine [5,10]. The reduction in the incidence of *S. pneumoniae* OM has resulted in an increase in the proportion of OM attributable to NTHi, and NTHi is now reported as the predominant cause of AOM [5,11,12].

In previous decades, greater than 95% of the cases of invasive disease caused by *H. influenzae* were due to strains with the type b capsule. However, vaccines based on the type b capsular polysaccharide have virtually eliminated such infections in regions where the vaccine is extensively used [13]. Nevertheless, NTHi strains continue to cause invasive disease principally in perinatal infants, young children, and those older than 65 years [1,14].

Several lines of evidence suggest that prevention of AOM due to NTHi is possible [15–17]. First, AOM is largely a disease of infants in whom the serum and mucosal antibodies directed against common pathogens are low [18]. Second, OM-prone children have lower levels of serum antibodies than healthy age-matched controls [19,20]. Third, individuals with immunodeficiencies are predisposed to repeated NTHi infections [21]. In addition, breast-feeding is associated both with a reduced frequency of AOM, and higher levels of serum antibodies against NTHi in the nursing infant [22].

Evidence from animal studies also supports the possibility of preventing AOM caused by NTHi. For example, it is possible to protect against challenge by pre-immunization with pilins from the challenge isolate, although cross protection against unrelated isolates was not developed [23]. Similarly, peptide motifs of the pilins were shown to protect, but only against homologous challenge [24]. This lack of cross protection presumably results from known sequence heterogeneity of the pilin proteins. Other studies have assessed protection afforded by antibodies to a number of virulence factors, including major and minor outer-membrane proteins (OMPs) and lipooligosaccharide [17]. Finally, an 11-valent *S. pneumoniae* vaccine using *H. influenzae* protein D as a carrier molecule afforded partial protection (a reduction of 35%) against NTHi OM in a human clinical trial [16,25,26].

Non-toxic, broadly cross-reactive immunoprotective NTHi antigens have yet to be identified, and there are significant obstacles to be addressed before a comprehensive vaccine can be developed for NTHi. Because of the known heterogeneity of surface associated moieties in the NTHi [27], an efficacious vaccine may require a multi-component design. While a few vaccine candidates have been identified, the development, production and clinical testing of vaccines against NTHi are still lacking [17]. To date, highly immunogenic surface components that elicit protective antibodies against mucosal infections by all strains of NTHi in the age-appropriate population have not been identified. As a first step to identifying suitable protective epitopes, we used a genomic analysis to identify conserved surface-exposed peptides and tested 10 of these for their in vivo antibody accessibility.

**Materials and Methods**

**Bacterial strains and growth conditions**

The NTHi strain R2866 was isolated from the blood of an immunocompetent child with clinical signs of meningitis subsequent to AOM [28]. We have previously utilized this strain in the infant rat model of invasive *H. influenzae* disease [29].
NTHi strain sequences used to generate alignments included sequences available through GenBank as well as multiple strains sequenced in-house. Sequences obtained through GenBank were from the following strains: 3655, 6P18H1, 7P49H1, PittAA, PittEE, PittGG, PittHH, PittII, R3021, R2846, R2866, 22.1–21, 22.4–21, 86-028NP and NT127. Strains sequenced in house were from our laboratory collection and included several selected from those typed by electrophoretic mobility of 15 metabolic enzymes [30]. These strains were selected to represent the breadth of the species as defined by electrophoretic type (ET) and were HI1373, HI1374, HI1388, HI1394, HI1408, HI1417 and HI1426 representing, respectively, ET’s 13, 26, 43, 53, 68, 77 and 86. An additional four clinical isolates selected from our collection were also sequenced: HI1722, HI1974, HI2114 and HI2116. Isolates of *H. influenzae* were routinely maintained on chocolate agar with bacitracin at 37°C. Broth cultures of *H. influenzae* were grown in brain heart infusion (BHI) agar supplemented with 10 μg/ml heme and 10 μg/ml β-NAD (supplemented BHI; sBHI).

**Genome sequencing of NTHi strains**

Chromosomal DNA was isolated from bacteria recovered from fresh 12 hour broth cultures using the DNeasy Blood and Tissue Kit (Qiagen) as described by the manufacturer. Genome sequences of the NTHi strains were determined at the Laboratory for Molecular Biology and Cytometry Research, University of Oklahoma Health Sciences Center.

NTHi samples were prepared using 50-ng of total genomic DNA according to Nextera DNA library kit protocols (Illumina Inc). Samples were indexed according to standard protocols so that they could be pooled together and sequenced simultaneously in a single run on the Illumina MiSeq using paired-end 150-bp (300 cycle) chemistry. Prior to sequencing, all libraries were run individually on the Agilent High Sensitivity DNA chip to confirm library quality and average insert size. Samples were pooled in equimolar amounts and 8pM of the pool was run on the sequencer. Per Illumina’s recommendation, phiX control was spiked into the library pool prior to loading for quality control purposes (5–10% phiX). Thirty to forty million reads total were collected for each run. Raw sequence data were aligned to a reference isolate using CLC Genomics Workbench (CLC Bio.) to identify single-nucleotide polymorphisms (SNPs) as well as regions with insertions or deletions (indels) or raw data files were assembled using CLC *de novo* assembly parameters.

The genome sequences generated herein were deposited in Genbank. Sequenced strains and corresponding accession numbers are as follows HI1373 (LFDP00000000), HI1374 (LFDO00000000), HI1388 (LFDN00000000), HI1394 (LFDM00000000), HI1408 (LFDJ00000000), HI1417 (LFDK00000000), HI1426 (LFDL00000000), HI1722 (LFFU00000000), HI1974 (LFJT00000000), HI2114 (LFFR00000000), and HI2116 (LFFS00000000).

**Identification of SEPs present in all NTHi strains**

Initially, the complement of putative surface-exposed proteins (SEPs) of the isolate NTHi 86-028NP was determined based on the reported annotation of this isolate [31]. For the purposes of this paper SEPs include characterized and putative OMPs as well as other secreted proteins. Hypothetical proteins were individually examined to determine the presence of leader sequences and/or other indicators that they may be secreted or membrane bound. All identified proteins were then used to query the presence of homologs in the other sequenced NTHi. Absence of a homolog in any of the sequenced NTHi excluded that protein from further consideration. Once each core SEP was identified, Geneious software was used to perform sequence alignments with all the known homologs of a given protein in all the available NTHi genomes.
Molecular modeling
The identified core SEP genes of NTHI 86-028NP were individually examined to determine homology to other known structurally defined proteins. Structures were generated using the Modeller algorithm [32,33], Swissmodel [34] and Phyre2 [35] via The Protein Model Portal [36]. Putative structures were compared and visualized using Chimera to determine potentially surface-exposed regions [37]. Proteins that shared no significant similarities with other modeled proteins were examined to determine regions indicative of secondary structure using PRED-TMBB, BOMP (β-barrel), and TMHMM (α-helix) [38–40].

Selection of peptides
From these models, predicted surface-exposed regions greater than 10 amino acids long were selected. Multiple sequence alignments were performed with each core protein. All NTHi homologs of each protein from both complete and partial gene and genome sequences were used to perform these alignments. For the majority of proteins, more than 40 NTHi sequences were aligned. External regions greater than 10 amino acids in length were further examined to identify the degree of conservation of sequence across the NTHi. Regions with high conservation were selected as potential antigens. Some selected external loops were longer than 25 amino acids. In these cases AbDesigner [41], was used to determine the most immunogenic region. A truncated synthetic peptide was then selected from this region for further study. Synthetic peptides with >95% purity were synthesized by SynBioSci Corp., Peptide 2.0 Inc., or Thermo Fisher. During synthesis, an aliquot of each peptide was conjugated to Keyhole limpet haemocyanin (KLH) to facilitate immunization studies. A second aliquot was conjugated to biotin for use in ELISA assays.

Immunization of rats
Antisera against each synthetic peptide were raised either in-house or by Thermo Fisher in two adult Sprague-Dawley rats (~300g) using an 80 day protocol. Initially a pre-immune bleed of approximately 1 ml was performed on each rat. On the following day rats were immunized with 100 μg of antigen in Complete Freund’s Adjuvant. Booster injections were performed on days 21, 42 and 62 with 50 μg of emulsified peptide preparation in Incomplete Freund’s Adjuvant. All immunizations were administered subcutaneously to the dorsum at four to six separate locations to minimize swelling and distress. On day 50, serum samples were collected and antibody titers determined by peptide specific ELISA. Samples with a titer in excess of 3200 were considered suitable for protection studies and these animals were exsanguinated on day 80. Antisera from Thermo Fisher were shipped on dry ice. All antisera were stored, frozen at -80°C until protection studies were performed.

Rat model of NTHi bacteremia
The rat model of bacteremia following intraperitoneal infection with H. influenzae was used to compare the abilities of antisera to protect against invasive disease as previously described [42–44]. Specified pathogen free (SPF), timed-pregnant Sprague-Dawley rats (Charles Rivers) were received approximately five days prior to giving birth. These pregnant females were single housed on hardwood litter with ad libitum access to water and a standard pelleted food (Purina Lab Rodent Diet 5001). They were maintained on a 12 hour light-dark cycle in separate forced air cubicles in a bio-containment facility (ABSL2) to prevent cross-contamination. Newborn pups from different mothers were pooled and randomly reassigned to the mothers (n = 8–10 pups per female).
In each experiment, cohorts of 4-day old infant rats were injected subcutaneously with 100 μl of either pre-immune serum, antiserum raised to a specific peptide, or PBS. The following day each infant rat was challenged by intraperitoneal injection of approximately 1.5x 10^5 CFU of R2866. Inocula were prepared as previously described [44], and the actual infective dosage was confirmed by quantitative plating. At 24 or 48 hours post-infection, blood samples (50 μl) were obtained from the anesthetized infant rats (gaseous isoflurane) by cardiac puncture. Bacterial titers were determined using a modified track-dilution method as previously described [44]. All plates were incubated at 37°C for 24–48 hours to quantify CFU/ml. The Fisher Exact Test was used to determine the statistical significance of differences in the fraction of animals developing bacteremia in different infant rat cohorts. The Kruskal-Wallis test was used to determine the statistical significance of differences in the mean bacteremic titers between groups of infant rats. A P value <0.05 was taken as statistically significant.

Ethics statement
This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols for use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Oklahoma Health Sciences Center (Protocol numbers 13-139-H and 14-029-I). Infected animals were monitored for signs of pain and stress at least twice daily following infection. Signs of pain and stress are gasping, writhing behavior, immobility, vocalization, hypothermia and abnormal color and were criteria for the affected animal to be immediately euthanized. No animals were euthanized due to signs of pain or stress in the study. All animals were euthanized by carbon dioxide inhalation following the blood draw.

Results
Immunological examination of HxuC peptides
Preliminary experiments were performed to gauge the likelihood that conserved surface-exposed peptides represent protective epitopes. These experiments were initiated when the available sequenced H. influenzae genomes were limited. Five complete genomes were utilized in these studies and were the originally sequenced isolate Rd KW20, a sequenced type b isolate 10810, and three NTHi isolates (86-028NP, R2866 and R2846). The protein of interest in these studies was the heme-hemopexin utilization protein HxuC [45,46]. The HxuC protein sequences from the five genome-sequenced isolates, as well as several stand-alone HxuC protein sequences from additional strains, were used to perform sequence alignments. At the same time a predicted molecular model was constructed and the putative surface-exposed regions were determined. Five regions showing a high degree of sequence conservation were selected for immunological examination (Table 1).

In a screening experiment the five KLH-conjugated peptides were mixed to provide a pentavalent preparation that was used to immunize two adult rats as described. Antisera raised to this pentavalent peptide preparation provided significant protection against NTHi bacteremia by comparison with both PBS control and pre-immune sera from the same animals (Fig 1A).

Having demonstrated that antisera raised to the pentavalent-peptide preparation were protective we examined each of the five HxuC-derived peptides individually. Antisera specifically against two of the peptides (HxuC1 and HxuC2) were highly protective (Fig 1). All animals receiving antisera to HxuC2 failed to develop bacteremia, while in the cohort receiving HxuC1 antisera 2 of 10 infected animals developed bacteremia (Fig 1B). In the two animals in the HxuC1-antisera treated group that developed bacteremia, the bacterial titers were approximately...
1000-fold less than control animals (Fig 1C). Antisera to the remaining three peptides from HxuC did not provide statistically significant protection against NTHi invasive disease.

Since certain peptides derived from HxuC gave rise to protective antisera we extended our study to include additional potentially surface-exposed proteins from *H. influenzae*. Since a highly effective vaccine is available to prevent type b disease, and type d strains are essentially avirulent we excluded strains 10810 and Rd KW20, and instead focused on the more clinically relevant NTHi strains.

Genome sequencing of genetically characterized diverse NTHi isolates

At the time that the HxuC peptides were selected, the number of sequenced genomes was too low to confidently determine conservation across the NTHi of any single gene and insufficient to determine the breadth of variation of each individual surface-exposed loop. Currently over

Table 1. Peptide Sequences Selected for Polyclonal Antiserum Production.

| Protein | Peptide Sequence |
|---------|------------------|
| HxuC1   | LYNNKTEKEQRKV    |
| HxuC2   | DHYDTSSKTVKYKD   |
| HxuC3   | APSMOERFVSAGHF   |
| HxuC4   | KGKDASGEALSNIAASK |
| HxuC5   | ENLDFRKYQPAFSLMEGTRN |
| ComE1   | TLMKDGY(I/Y)YYLNGSQQSGKQ |
| Hel1    | DSNPSYGQNVQKNKFDK | |
| Hel2    | GDLDFGN(T/S)VYGGKLNDRR |
| TdeA1   | QRRVDISTNSA(T)SHK |
| OmpU1   | SWDYQKSTSNHAHYRDKR |

a Annotated name of the protein in the NTHi isolates (suffix indicates peptide number).
b Amino acid sequence of the select peptide. Residues in parentheses represent variant residues at that single position.

doi:10.1371/journal.pone.0136867.t001

1000-fold less than control animals (Fig 1C). Antisera to the remaining three peptides from HxuC did not provide statistically significant protection against NTHi invasive disease.

Since certain peptides derived from HxuC gave rise to protective antisera we extended our study to include additional potentially surface-exposed proteins from *H. influenzae*. Since a highly effective vaccine is available to prevent type b disease, and type d strains are essentially avirulent we excluded strains 10810 and Rd KW20, and instead focused on the more clinically relevant NTHi strains.

Genome sequencing of genetically characterized diverse NTHi isolates

At the time that the HxuC peptides were selected, the number of sequenced genomes was too low to confidently determine conservation across the NTHi of any single gene and insufficient to determine the breadth of variation of each individual surface-exposed loop. Currently over

---

Fig 1. Protection afforded by anti-HxuC antisera in the infant rat model of NTHi bacteremia. Panel A) Percentage of infected infant rats pretreated with pentavalent anti-HxuC antisera with detectable bacteremia 48 hours after infection. Twenty-four hours prior to infection cohorts of 10 infant rats were pretreated with phosphate-buffered saline (PBS), pre-immune serum (PIS) or peptide-specific antiserum (PSAS). Using Fisher’s exact test to compare percentages of bacteremic pups *P* = 0.0011 for PBS vs PSAS and *P* = 0.0198 for PIS vs PSAS. Panel B) Percentage of infected infant rats pretreated with antisera against specific HxuC peptides with detectable bacteremia 48 hours after infection. Twenty-four hours prior to infection cohorts of infant rats were pretreated with phosphate-buffered saline (PBS; cohort of 8 rats), HxuC1 specific antisera (HxuC1; cohort of 10 rats), or HxuC2 specific antisera (HxuC2; cohort of 10 rats). Using Fisher’s exact test to compare percentages of bacteremic pups *P* = 0.0011 for PBS vs HxuC1 and *P* = 0.0001 for PBS vs HxuC2. Panel C) Bacteremic titers in infected infant rats pretreated with antisera against specific HxuC peptides 48 hours after infection. Filled dots represent the bacteremic titer in each individual animal in a cohort. The unfilled dot represents the average bacteremic titers in all members of the cohort. Values of 1 or below represent animals with no detectable bacteremia. Using the Kruskal-Wallis test to compare bacteremic titers(means ± SD) *P* = 0.002 for PBS vs HxuC1 and *P* = 0.0004 for PBS vs HxuC2.

doi:10.1371/journal.pone.0136867.g001
30 NTHi genome sequences are publicly available, however, only nine of these sequences are complete. The rest are only useful to confirm the presence and sequence of a particular gene within the respective genome. However, since all genes may not be present, absence of an SEP in an inadequately sequenced genome cannot exclude it from further consideration as a core SEP. To enhance the probability that the peptide selection included regions found in all NTHi, the genomes of an additional 11 NTHi isolates were sequenced. To assure genetic diversity, isolates for sequencing were chosen from strains previously used to define the breadth of the species by electrophoretic typing [30], as well as other NTHi clinical isolates from our culture collection. A multi locus sequence analysis system based on five gene loci (adk, pgi, recA, infB, and 16S rRNA) was applied to these newly sequenced genomes [47]. Using these concatenated sequences from all the sequenced NTHi a dendrogram was constructed to demonstrate the distribution of the newly sequenced isolates within the species (Fig 2).

![Fig 2. Distribution of sequenced NTHi isolates. Neighbor joining dendogram of NTHi strains used in this study. The tree is rooted with Eschericia coli MG1655 and is based on sequence comparisons of the concatenated adk, pgi, recA, infB and 16s rRNA gene sequences, with bootstrap values of greater than 50% of 1,000 bootstraps indicated. Also included are several non NTHi sequences; Hp (H. parainfluenzae T3T1), HH (H. haemolyticus ATCC 33390) and the H. influenzae strains Rd KW20 and 10810. doi:10.1371/journal.pone.0136867.g002](image-url)
Identification of core SEPs present in the NTHi

Initially we identified the complement of putative SEPs in the NTHi strain 86-028NP. Such proteins were identified based on known annotation, the presence of export signal sequences, and their similarity to known OMPs in other species. Proteins that localize exclusively to the periplasmic space were in general excluded. However, some proteins considered periplasmic have been shown to be also externally expressed; for example Pal has recently been shown to be inserted in the OM in two distinct orientations \[48,49\]. Thus, periplasmic proteins that might be anchored to the OM were retained unless definitive evidence exists that they are not externally located. Each coding region was analyzed using PSORTb and PSORT \[50\]. Proteins with localization signals indicating export across the cytoplasmic membrane were analyzed for homology to experimentally determined OMPs from other organisms. Finally, those proteins in which localization to the OM was putative were further subjected to analysis for structural motifs indicative of membrane-spanning domains. Ninety-six SEPs were identified in strain 86-028NP. This data set was then used to establish the presence of each allele in each of the 21 complete NTHi genome sequences. From these 21 complete sequences, a set of 56 NTHi core SEPs was identified (Table 2). Using all of the available genome and stand-alone gene sequences, the sequence conservation of each individual OMP gene was determined.

Molecular modeling to assess surface-exposed regions of the SEPs

The core SEPs fall into three main structural categories, β-barrel, α-helix and amorphous. The majority of OMPs that are embedded in the membrane adopt the β-barrel structure while the remaining have an α-helix based structure. The OMPs that are either secreted or bound to the outer membrane by a small lipophilic tail are more amorphous, often with no clearly defined common structural features. Our previous studies focused on HxuC, a defined OMP with the β-barrel conformation. In the outer membrane, such proteins fold to create a barrel-like structure with a core, or plug, which can be shifted to allow ingress of a transported molecule (Fig 3) \[51,52\]. Referred to as "gated porins", these OMPs have been the focus of numerous X-ray crystallization studies. Since they are structurally constrained, it is possible to both map the NTHi OMPs to those with known crystal structure and to use computer assisted molecular modeling algorithms to determine the potential externally-exposed loops. In some cases an external loop is small, comprising one or two residues while other loops are longer and show variable degrees of sequence heterogeneity. The proposed structure of HxuC is shown to demonstrate the topography and location of the OM loops (Fig 3). Adjacent to it are two sequence alignments that correspond to the indicated loops (for simplicity, only 5 genome sequences are included). Loop 8 is highly heterologous and thus does not constitute a good candidate for further study (Fig 3). In contrast loop 6 is conserved and satisfies our criteria for selection as a suitable peptide motif for generation of antisera. Loop 6 corresponds to the protective peptide HxuC2 described above. Similarly, the OMPs determined to have the α-helix conformation were mapped where possible to the conserved residues of OMPs in other species that have deduced crystal structures. OMPs which are loosely attached to the membrane have proven more difficult to map. To determine potentially exposed regions on these OMPs, we utilized numerous molecular prediction algorithms to identify potential transmembrane and exposed residues. These are usually based on hydrophobicity/hydrophilicity plots and periodicity of residues in these regions. Such analyses can be used to potentially identify regions of interest without providing an elaborated structure as shown for NTHI1734m (Fig 3). Of the 56 core OMPs, 24 appear to have the β-barrel structure and four the α-helix structure while the rest are amorphous structures anchored to the membrane by a polypeptide tail. To date, 41 of the core OMPs have been sufficiently modeled to identify surface exposed peptide motifs.
Table 2. Core SEPs of the NTHi<sup>a</sup>.

| 86-026NP locus | Gene designation | Rd KW20 locus | Gene description | Probable Type<sup>b</sup> |
|---------------|------------------|---------------|------------------|---------------------------|
| NTHI0579      | ytfL             | HI0452        | Putative hemolysin (probable inner membrane) | α-helix |
| NTHI0576      |                 | HI0449        | Conserved hypothetical protein | Amorphous |
| NTHI0560      | comE             | HI0435        | Outer membrane secretin ComE | Amorphous |
| NTHI0522      | ompP1            | HI0401        | Outer membrane protein P1 | β-barrel |
| NTHI0509      | yeaY             | HI0389        | Slp family OM lipoprotein | Amorphous |
| NTHI0501      | pal              | HI0381        | Peptidoglycan associated OMP | Amorphous |
| NTHI0486      | pilF             | HI0366        | Transformation and Tfp-related protein PilF | Amorphous |
| NTHI0449      | oapB             | HI0366        | Opacity associated adhesion protein B | Amorphous |
| NTHI0448      | oapA             | HI0330        | Opacity associated adhesion protein A | α-helix |
| NTHI0409      | pilA             | HI0299        | Type II secretory pathway, major preplin PilA | Amorphous |
| NTHI0370      | hxb              | HI0263        | Heme-hemopexin utilization protein B | β-barrel |
| NTHI0369      | hxe              | HI0262        | Heme-hemopexin utilization protein C | β-barrel |
| NTHI0363      | nipB             | HI0256        | OMP assembly complex subunit NipB/BamC | Amorphous |
| NTHI0354      | hap              | HI0247        | Adhesion and penetration protein precursor | β-barrel |
| NTHI0353      |                 | HI0246        | OMP assembly protein | Amorphous |
| NTHI0338      | mltF             | HI0232        | Membrane-bound lytic murein transglycosylase | Amorphous |
| NTHI0303      | nucA             | HI0206        | 5'-nucleotidase NucA | Amorphous |
| NTHI0267      | ompE             | HI0178        | Adhesin protein E | Amorphous |
| NTHI0266      | bamD             | HI0177        | OMP assembly complex subunit BamD | Amorphous |
| NTHI0252      | yfgG             | HI0162        | Putative lipoprotein | Amorphous |
| NTHI0225      | ompP2            | HI0139        | Outer membrane protein P2 | β-barrel |
| NTHI0220      |                 | HI0134        | Putative OMP assembly protein | β-barrel |
| NTHI0205      | mltA             | HI0117        | Membrane-bound lytic murein transglycosylase A | Amorphous |
| NTHI0202      | hemR             | HI0113        | Probable TonB-dependent heme receptor | β-barrel |
| NTHI1987      | yccT             | HI1681        | Conserved hypothetical protein | Amorphous |
| NTHI1957      | lppC             | HI1655        | Lipoprotein LppC | Amorphous |
| NTHI1954      | spr              | HI1652        | Lipoprotein Spr, probable murein endopeptidase | Amorphous |
| NTHI1930      |                 | HI1236m       | Conserved hypothetical protein | β-barrel |
| NTHI1668      | tdeA             | HI1462        | Outer membrane efflux porin TdeA | β-barrel |
| NTHI1794m     |                 | HI1369        | Probable TonB-dependent transporter | β-barrel |
| NTHI1473      | lpp              | HI1579        | 15 kDa peptidoglycan-associated lipoprotein | α-helix |
| NTHI1435      | lolB             | HI1607        | OM lipoprotein insertion protein LolB | Amorphous |
| NTHI1390      | hup              | HI1217        | Heme utilization protein | β-barrel |
| NTHI1387      |                 | HI1215        | Conserved hypothetical protein | Amorphous |
| NTHI1342      | olpA             | HI1174m       | Probable surface adhesion OlpA | β-barrel |
| NTHI1332      | ompP5            | HI1164        | Outer membrane protein OmpP5 | β-barrel |
| NTHI1262      |                 | HI1098m       | Conserved hypothetical protein | Amorphous |
| NTHI1171      | ompU             | HI0997m       | Putative OM protein OmpU | β-barrel |
| NTHI1169      | tbp2             | HI0995        | Transferrin binding protein 2 | Amorphous |
| NTHI1168      | tbp1             | HI0994        | Transferrin binding protein 1 | β-barrel |
| NTHI1164      | igA1             | HI0990        | IgA1 protease | β-barrel |
| NTHI1140      |                 | HI0966        | Conserved hypothetical protein | β-barrel |
| NTHI1133      | ycfL             | HI0960        | Putative lipoprotein YcfL | Amorphous |
| NTHI1101      |                 | HI0930        | Putative lipoprotein | Amorphous |
| NTHI1091      | lptE             | HI0922        | LPS assembly OM complex LptDE component | β-barrel |
| NTHI1084      | bamA             | HI0917        | OM protein assembly factor BamA | β-barrel |
| NTHI1005      | smpA             | HI0838        | OMP assembly complex subunit SmpA/BamE | Amorphous |

(Continued)
These include 16 of the β-barrels, 2 of the α-helical proteins and 23 of the amorphous structures (Table 2). Combining putative structure with the sequence alignments allows identification of conserved putatively surface exposed regions (S1 Table and S2 Table).

Characterization of protective epitopes

Although the structural mapping indicates conserved surface exposed regions, determination of whether these regions are antibody accessible in vivo requires empirical analysis. From the

---

Table 2. (Continued)

| 86-026NP locus | Gene designation | Rd KW20 locus | Gene description | Probable Typea |
|----------------|------------------|---------------|------------------|----------------|
| NTHI0921       | mltC             | HI0761        | Membrane bound-lytic murein transglycosylase C | Amorphous |
| NTHI0889       | lptD             | HI0730        | LPS assembly OM complex LptDE, protein LptD | β-barrel |
| NTHI0849       | mlaA             | HI0718        | Outer membrane lipid asymmetry protein MlaA | α-helix |
| NTHI0840m      | hgpC             | HI0712        | Hemoglobin-haptoglobin utilization protein C | β-barrel |
| NTHI0821       | tpsA             | HI0698        | Two-partner secretion system protein | β-barrel |
| NTHI0820       | tpsB             | HI0696        | Two-partner secretion system protein | β-barrel |
| NTHI0816       | hel              | HI0693        | Outer membrane protein P4 | Amorphous |
| NTHI0811       | glpQ             | HI0689        | Glycerophosphodiesterase | Amorphous |
| NTHI0782       | hgpB             | HI0661        | Hemoglobin-haptoglobin utilization protein B | β-barrel |

Proteins were initially identified as putative members of the SEP complement using PSORT and PSORTb analysis of cellular localization of predicted protein sequences and/or due to homology to known OM localized proteins. Lists were narrowed by excluding SEPs not conserved across the sequenced NTHi isolates and removal of proteins that lacked a strong probability of being localized to the outer membrane and having surface exposed residues.

Probable structure based on modeling. PRED-TMBB and BOMP (β-barrel), TMHMM (α-helix), amorphous for proteins that fit neither model or have components of both. Bolding indicates proteins that have been modelled and for which conserved peptides have been identified (see S1 Table).

doi:10.1371/journal.pone.0136867.t002
sequence alignments, 5 external OM loops that showed conservation and that were a minimum of 10 amino acid residues in length were selected. The 5 selected epitopes were in addition to the 5 from HxuC peptides examined above. The 5 new epitopes were from 4 different proteins ComE, Hel, TdeA and OmpU and were designated respectively ComE1, Hel1, Hel2, TdeA1 and OmpU1 (Table 2).

Each of these five epitopes was used in our immunization protocol. The TdeA1 peptide did not induce an antibody titer sufficient to proceed with further study of that antigen. Antisera raised to the OmpU1 peptide did not provide a significant protective effect in the infant rat model. Five of 9 infant rats in the OmpU1-antisera treated cohort and 9 of 10 infant rats in the control cohort had detectable bacteremia ($P = 0.14$). Seven of 10 infant rats pretreated with antiserum raised to ComE1 failed to develop bacteremia (Fig 4A). While the rate of bacteremia of the anti-ComE1 treated group was significantly lower than the rate for the PBS treated group ($P = 0.0031$) it did not significantly differ from the pre-immune serum treated group ($P = 0.0698$) probably to a small cohort size in the latter group (Fig 4A). However, the bacteremic titer in the anti-ComE1 antisera cohort was significantly lower than seen in either of the control groups (Fig 4B). Antiserum raised to the Hel1 was significantly protective when given to infant rats 24 hours prior to challenge with NTHi strain R2866. While all rats pretreated with either PBS or the pre-immune serum had detectable bacteremia 24 hours after infection 5 of 10 animals pretreated with anti-Hel1 antiserum were abacteremic ($P = 0.0325$) (Fig 4C). Bacteremic titers were also significantly lower in those rats pretreated with anti-Hel1 antiserum than those rats pretreated with either PBS or pre-immune serum (Fig 4D). Antiserum raised to the Hel2 peptide gave similar results to those seen for Hel1 (data not shown).

Discussion

There currently are no vaccines licensed for prevention of infection caused by NTHi. Although several potential vaccine candidates against NTHi have been evaluated, robust cross protection against NTHi strains has not been observed. For example the *H. influenzae* protein D component of the pneumococcal vaccine has demonstrated a 35% protection rate in a clinical trial [25]. From our studies protein D (encoded by *glpQ*) exhibits multiple variant residues among NTHi strains. This may account for the low protection rate. Alternatively, expression of protein D may vary among different NTHi strains. Thus, failure of previous vaccine candidates may arise in part from problems of target protein conservation and/or biological accessibility. In our study we sought to obviate the problem of lack of conservation. An initial step in this study was to identify the conserved core SEPs shared by all the NTHi. Most NTHi strains possessed approximately 90 genes encoding SEPs. Of these, several are either distinct to a particular isolate or restricted to a few isolates, and are thus unsuited as vaccine candidates. For example, the Hmw1A, Hmw1B, Hmw2A, Hmw2B, HgpA, HgpD and HgpE proteins are common among the NTHi, but not conserved in all [53,54]. Clearly, a large set of genomic sequences is required to exclude common, yet non-conserved proteins. From the 21 genomically sequenced, diverse NTHi isolates we have narrowed the core set of SEPs to 56 proteins. As more genomic sequences become available it is possible that this number may decrease further. However, based on our selection of strains previously characterized to represent the genetic breadth of the species, the number of genomes sequenced, and the conservation of core genes predicted by computer based models [55], the chance of elimination of a gene with a further increase in the number of sequenced genomes is possible but unlikely. Thus, we propose that 56 genes encode the core SEPs of the NTHi. The conservation across the species of these core SEPs suggests they are required for the survival and/or cellular fitness of the NTHi. Thus, finding...
conserved regions of these proteins was not surprising and probably represents their essential functionality for NTHi survival. Of these 56 core SEPs the structures of 41 have been modeled. Initially, putative externally exposed loops were selected from the modeled SEPs based on the length of the conserved region. Regions containing greater than 10 amino acids were

![Graph A](image1)

![Graph B](image2)

![Graph C](image3)

![Graph D](image4)

**Fig 4.** Protection afforded by antisera raised against ComE and Hel derived peptides in the infant rat model of NTHi bacteremia. Panel A) Percentage of infected infant rats pretreated with anti-ComE1 antiserum with detectable bacteremia 24 hours after infection. Twenty-four hours prior to infection cohorts of infant rats were pretreated with phosphate-buffered saline (PBS; cohort of 9 rats), pre-immune serum (PIS; cohort of 9 rats) or anti-ComE1 antiserum (ComE1; cohort of 10 rats). Using Fisher’s exact test to compare percentages of bacteremic pups $P = 0.0031$ for PBS vs ComE1 and $P = 0.0698$ for PIS vs ComE1. Panel B) Bacteremic titers in infant rats pretreated with anti-ComE1 antiserum 24 hours after infection. Filled dots represent the bacteremic titer in each individual animal in a cohort. The unfilled dot represents the average bacteremic titers in all members of the cohort. Values of 1 or below represent animals with no detectable bacteremia. Using the Kruskal-Wallis test to compare bacteremic titers (mean ± SD) $P = 0.07$ for PBS vs PIS, $P = 0.0002$ for PBS vs ComE1 and $P = 0.01$ for PIS vs ComE1. Panel C) Percentage of infected rats pre-treated with anti-Hel1 antiserum with detectable bacteremia 24 hours after infection. Twenty-four hours prior to infection cohorts of infant rats were pretreated with phosphate-buffered saline (PBS; cohort of 10 rats), pre-immune serum (PIS; cohort of 9 rats) or anti-Hel1 antiserum (Hel1; cohort of 10 rats). Using Fisher’s exact test to compare percentages of bacteremic pups $P = 0.0325$ for both PBS vs Hel1 and PIS vs Hel1. Panel D) Bacteremic titers in infant rats pretreated with anti-Hel1 antiserum with detectable bacteremia 24 hours after infection. Filled dots represent the bacteremic titer in each individual animal in a cohort. The unfilled dot represents the average bacteremic titers in all members of the cohort. Values of 1 or below represent animals with no detectable bacteremia. Using the Kruskal-Wallis test to compare bacteremic titers (mean ± SD) $P = 0.15$ for PBS vs PIS, $P = 0.0003$ for PBS vs Hel1 and $P = 0.0005$ for PIS vs Hel1.

doi:10.1371/journal.pone.0136867.g004
selected as possible linear epitopes. Over 80 such regions that showed complete identity were identified (S2 Table). The presence of conserved external loops suggests that these regions play a critical role in protein function. Alternatively, variations in these regions may be unnecessary if the regions are not available to the human immune system.

Almost 200 peptides from the core SEPs satisfied our initial screening criteria. While computer-assisted modeling and bioinformatics may identify putative exposed regions, antibody accessibility in vivo must be confirmed empirically. A number of confounding factors may render a putative epitope inaccessible. Gene regulation, spatial orientation of the loop itself, shielding by other loops and steric hindrance can render potential targets antibody inaccessible. To empirically determine in vivo antibody accessibility, an animal model was utilized. Of the 200 candidate peptides, 10 have been analyzed to determine their biological accessibility (Table 1).

Initially, the 5 peptides targeting regions of HxuC were analyzed. Peptides HxuC1 and HxuC2 generated antisera that were protective while HxuC3, HxuC4 and HxuC5 did not. Since these experiments were performed, new sequencing data have revealed that HxuC5 has two variant residues in the middle of the loop. In two of the newer sequences an isoleucine residue is substituted for a methionine residue, and in a third sequence a lysine is substituted for an arginine. The protein in strain R2866 has both the methionine and arginine residues. Thus, sequence heterogeneity cannot explain the lack of protection observed by antisera raised to peptide HxuC5.

Based on the availability of genomic sequences at the time of these studies, all of the peptides (with the exception of ComE1, Hel2 and TdeA) were designed to loops that were absolutely conserved across the NTHi. Peptides ComE1, Hel2 and TdeA were designed to match the inherent variability of the corresponding OM loop. Each had a single variant residue. To address this heterogeneity, two peptides were made for each sequence and an equimolar mixture of each was used to inoculate the adult rats. The outer membrane loop that the ComE1 peptide was designed from was estimated at 33 amino residues. From this a 20 residue region was selected based on maximal immunogenicity predicted by the AbDesigner algorithm [41]. Similarly the 20-mer peptide Hel1 was selected from an estimated exposed loop of 27 residues. Antisera raised to both of the Hel peptides and the ComE1 peptide were protective. Analysis of the specific immunogenicity of each peptide was beyond the scope of the present study.

It is unknown why only certain peptides stimulate protective antisera. Of the five synthetic peptide antigens targeting the HxuC protein, only two provided significant protection. Since the structure of the gated porins is well defined and the target appears surface exposed, steric hindrance may interfere with antibody accessibility to the non-protective loops. The same may also be true for antisera raised to the OmpU1 peptide since OmpU has a known β-barrel structure. Unlike HxuC, ComE and Hel are both amorphous structures with a suspected membrane anchor. In situ, the majority of the protein would be surface exposed. Selection of peptides from these sequences was based primarily on regions of predicted α-helices. While each peptide was modeled to be surface exposed, the clear protection against NTHi challenge in the infant rat provides empirical proof of surface exposure.

In summary, NTHi is an important public health burden without an obvious vaccine target. We hypothesize that likely successful targets may be regions of proteins that are both conserved and antibody available in vivo. Screening of well-characterized NTHi genome sequences identified 56 core SEPs present in all strains. These proteins were modeled to identify regions which may be available on the outer surface. Antisera raised to 10 externally exposed, conserved peptides were tested for their in vivo passive protective capacity. Of the 10 peptides, 5 induced sera that provided protection. These data provide proof of principle that certain conserved peptides may be antibody available and may be useful components of a vaccine. Additionally, these data
provide a foundation to identify many other peptide targets for antibody production to protect against NTHi infection.

**Supporting Information**

S1 Table. Potential surface-exposed, highly conserved peptides of the NTHi.

(XLSX)

S2 Table. External peptides with 100% conservation.

(XLSX)

**Acknowledgments**

We thank Timothy VanWagoner for bioinformatics support, Huda Mussa for assistance with sequencing and Brett Cole for assistance with animal studies. We thank Arnold Smith for inspiration and persistence in understanding the basic biology of *H. flu*..

The authors gratefully acknowledge the Children’s Hospital Foundation for promoting the Department of Pediatrics Research Infrastructure. The Foundation provided no financial support for this specific project.

**Author Contributions**

Conceived and designed the experiments: PWW TWS DJM TLS. Performed the experiments: PWW TWS DJM. Analyzed the data: PWW TWS DJM. Wrote the paper: PWW TWS DJM TLS.

**References**

1. van Eldere J, Slack MP, Ladhani S, Cripps AW (2014) Non-typeable *Haemophilus influenzae*, an under-recognised pathogen. Lancet Infect Dis 14: 1281–1292. doi: 10.1016/S1473-3099(14)70734-0 PMID: 25012226
2. Alikhan MM, Lee FE (2014) Understanding nontypeable *Haemophilus influenzae* and chronic obstructive pulmonary disease. Curr Opin Pulm Med 20: 159–164. doi: 10.1097/MCP.0000000000000023 PMID: 24441573
3. Pichichero ME (2013) Otitis Media. Pediatr Clin North Am 60: 391–407. doi: 10.1016/j.pclin.2012.12.007 PMID: 23481107
4. Moghaddam SJ, Ochoa CE, Sethi S, Dickey BF (2011) Nontypeable *Haemophilus influenzae* in chronic obstructive pulmonary disease and lung cancer. Int J Chron Obstruct Pulmon Dis 6: 113–123. doi: 10.2147/COPD.S15417 PMID: 21407824
5. Coker TR, Chan LS, Newberry SJ, Limbos MA, Suttorp MJ, Shekelle PG, et al. (2010) Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children. A systematic review. JAMA 304: 2161–2169. doi: 10.1001/jama.2010.1651 PMID: 21081729
6. Smith-Vaughn HC, Srirakhash KS, Mathews JD, Kemp DJ (1997) Nonencapsulated *Haemophilus influenzae* in aboriginal infants with otitis media: prolonged carriage of P2 porin variants and evidence for horizontal P2 gene transfer. Infect Immun 65: 1468–1474. PMID: 9119489
7. Giebink GS (1989) The microbiology of otitis media. Pediatr Infect Dis 8: S18–S20.
8. Ahmed S, Shapiro NL, Bhattacharyya N (2014) Incremental health care utilization and costs for acute otitis media in children. Laryngoscope 124: 301–305. doi: 10.1002/lary.24190 PMID: 23649005
9. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P (2003) Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 22: 10–16. PMID: 12544402
10. Jansen AG, Hak E, Veenhoven RH, Damaoiseaux RA, Schilder AG, Sanders EA (2009) Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev CD001480. doi: 10.1002/14651858.CD001480.pub3 PMID: 19370566
11. Casey JR, Pichichero ME (2004) Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr Infect Dis J 23: 824–828. PMID: 15361720
12. Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, et al. (2004) Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 23: 829–833. PMID: 15361721

13. Ladhani SN (2012) Two decades of experience with the Haemophilus influenzae type b conjugate vaccine in the United Kingdom. Clin Ther 34: 385–399. doi: 10.1016/j.clinthera.2011.11.027 PMID: 22244051

14. Blain A, MacNeil J, Wang X, Bennett N, Farley MM, Harrison LH, et al. (2014) Invasive Haemophilus influenzae Disease in Adults >/= 65 Years, United States, 2011. Open Forum Infect Dis 1: ofu044. doi: 10.1093/ofid/ofu044 PMID: 25734116

15. Cripps AW, Otczyk DC, Kyd JM (2005) Bacterial otitis media: a vaccine preventable disease? Vaccine 23: 2304–2310. PMID: 15755616

16. Schuerman L, Borys D, Hoet B, Forsgren A, Prymula R (2009) Prevention of otitis media: now a reality? Vaccine 27: 5748–5754. doi: 10.1016/j.vaccine.2009.07.070 PMID: 19666154

17. Murphy TF (2015) Vaccines for Nontypeable Haemophilus influenzae. The Future is Now. Clin Vaccine Immunol doi: 10.1128/CVI.00089-15

18. Faden H, Duffy L, Williams A, Krystofik DA, Wolf J (1995) Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life. J Infect Dis 172: 132–135. PMID: 7779903

19. Faden H (2001) The microbiologic and immunologic basis of recurrent otitis media in children. Eur J Pediatr 160: 407–413. PMID: 11475577

20. Veenhoven R, Rijkers G, Schilder A, Adelmeijer J, Uiterwaal C, Kuis W, et al. (2004) Immunoglobulins in otitis-prone children. Pediatr Res 55: 159–162. PMID: 14561788

21. Samuelson A, Borrelli S, Gustafson R, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367: 740–747. PMID: 16517274

22. Sabirov A, Casey JR, Murphy TF, Pichichero ME (2009) Breast-feeding is associated with a reduced frequency of acute otitis media and high serum antibody levels against NTHi and outer membrane protein vaccine antigen candidate P6. Pediatr Res 66: 565–570. doi: 10.1203/PDR.0b013e3181b4f8a6 PMID: 19581824

23. Karasic RB, Beste DJ, To SC, Doyle WJ, Wood SW, Carter MJ, et al. (1989) Evaluation of pilus vaccines for prevention of experimental otitis media caused by nontypable Haemophilus influenzae. Pediatr Infect Dis S62–S65.

24. Novotny LA, Clements JD, Bakaletz LO (2011) Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypable Haemophilus influenzae. Mucosal Immunol 4: 456–467. doi: 10.1038/mi.2011.6 PMID: 21326197

25. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: evidence for persistent colonizations. Scand J Infect Dis 27: 303–313. PMID: 16558061

26. Forsgren A, Riesbeck K, Janson H (2008) Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 46: 726–731. doi: 10.1086/527396 PMID: 18230042

27. Barenkamp SJ (2004) Rationale and prospects for a nontypable Haemophilus influenzae vaccine. Pediatr Infect Dis J 23: 461–462. PMID: 15131472

28. Nizet V, Colina KF, Aimquist JR, Rubens CE, Smith AL (1996) A virulent nonencapsulated Haemophilus influenzae. J Infect Dis 173: 180–186. PMID: 8537657

29. Hempel RJ, Morton DJ, Seale TW, Whitby PW, Stull TL (2013) The role of the RNA chaperone Hfq in Haemophilus influenzae pathogenesis. BMC Microbiol 13: 134. doi: 10.1186/1471-2180-13-134 PMID: 23767779

30. Musser JM, Barenkamp SJ, Granoff DM, Selander RK (1986) Genetic relationships of serologically nontypable and serotype b strains of Haemophilus influenzae. Infect Immun 52: 183–191. PMID: 3485574

31. Harrison A, Dyer DW, Gillaspy A, Ray WC, Mungur R, Carson MB, et al. (2005) Genomic sequence of an otitis media isolate of nontypeable Haemophilus influenzae: comparative study with H. influenzae serotype d, strain KW20. J Bacteriol 187: 4627–4636. PMID: 15968074

32. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779–815. PMID: 8254673

33. Fiser A, Do RK, Sali A (2000) Modeling of loops in protein structures. Protein Sci 9: 1753–1773. PMID: 11045621
34. Arnold K, Bordoli L, Kopp J, Schwede T (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22: 195–201. PMID: 16301204
35. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ (2015) The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 10: 845–858. doi: 10.1038/nprot.2015.053 PMID: 25950237
36. Haas J, Roth S, Arnold K, Kiefer F, Schmidt T, Bordoli L, et al. (2013) The Protein Model Portal—a comprehensive resource for protein structure and model information. Database 2013: bat031. doi: 10.1093/database/bat031 PMID: 23624946
37. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25: 1605–1612. doi: 10.1002/jcc.20084 PMID: 15264254
38. Bagos PG, Liakopoulos TD, Spyropoulos IC, Hamodrakas SJ (2004) PRED-TMBB: a web server for predicting the topology of beta-barrel outer membrane proteins. Nucleic Acids Res 32: W400–W404. PMID: 15215419
39. Berven FS, Flikka K, Jensen HB, Eidhammer I (2004) BOMP: a program to predict integral beta-barrel outer membrane proteins encoded within genomes of Gram-negative bacteria. Nucleic Acids Res 32: W394–W399. PMID: 15215418
40. Krogh A, Larsson B, von HG, Sonnhammer EL (2001) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 305: 567–580. doi: 10.1006/jmbi.2000.4315 S0022-2836(00)94315-8 [pii]. PMID:11152613
41. Pisitkun T, Hoffert JD, Saeed F, Knepper MA (2012) NHLBI-AbDesigner: an online tool for design of peptide-directed antibodies. Am J Physiol Cell Physiol 302: C154–C164. doi: 10.1152/ajpcell.00325.2011 PMID: 21956165
42. Smith AL, Smith DH, Averill DR, Marino J, Moxon ER (1973) Production of Haemophilus influenzae b meninges in infant rats by intraperitoneal inoculation. Infect Immum 8: 278–290. PMID: 4542033
43. Seale TW, Morton DJ, Whitby PW, Wolf R, Kosanke SD, VanWagoner TM, et al. (2006) Complex role of hemoglobin and hemoglobin-haptoglobin binding proteins in Haemophilus influenzae virulence in the infant rat model of invasive infection. Infect Immun 74: 6213–6225. PMID: 16966415
44. Morton DJ, Smith A, Ren Z, Madore LL, VanWagoner TM, Seale TW, et al. (2004) Identification of a haem-utilization protein (Hup) in Haemophilus influenzae. Microbiology 150: 3923–3933. PMID: 15583146
45. Hanson MS, Pelzel SE, Latimer J, Muller-Eberhard U, Hansen EJ (1992) Identification of a genetic locus of Haemophilus influenzae type b necessary for the binding and utilization of heme bound to human hemopexin. Proc Natl Acad Sci USA 89: 1973–1977. PMID: 15426995
46. Morton DJ, Seale TW, Madore LL, VanWagoner TM, Whitby PW, Stull TL (2007) The haem-haemopexin utilization gene cluster (hxuCBA) as a virulence factor of Haemophilus influenzae. Microbiology 153: 215–224. PMID: 17185550
47. McCrea KW, Xie J, LaCross N, Patel M, Mukundan D, Murphy TF, et al. (2008) Relationships of nontypeable Haemophilus influenzae strains to hemolytic and nonhemolytic Haemophilus haemolyticus strains. J Clin Microbiol 46: 406–416. PMID: 18039799
48. Michiel LV, Snyder J, Schmidt R, Millilo J, Grimald K, Kalmeta B, et al. (2013) Dual orientation of the outer membrane lipoprotein P6 of nontypeable Haemophilus influenzae. J Bacteriol 195: 3252–3259. doi: 10.1128/JB.00185-13 PMID: 23687267
49. Michiel LV, Shaw J, MacPherson V, Barnard D, Bettingger J, D’Arcy B, et al. (2015) Dual orientation of the outer membrane lipoprotein Pal in Escherichia coli. Microbiology.
50. Yu NY, Wagner JR, Laird MR, Melli G, Rey S, Lo R, et al. (2010) PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics 26: 1608–1615. doi: 10.1093/bioinformatics/btp249 PMID: 20472543
51. Postle K, Kadner RJ (2003) Touch and go: tying TonB to transport. Mol Microbiol 49: 869–882. PMID: 12890014
52. Wiener MC (2005) TonB-dependent outer membrane transport: going for Baroque? Curr Opin Struct Biol 15: 394–400. PMID: 16039843
53. St Geme JW, Yeo HJ (2009) A prototype two-partner secretion pathway: the Haemophilus influenzae HMW1 and HMW2 adhesin systems. Trends Microbiol 17: 355–360. doi: 10.1016/j.tim.2009.06.002 PMID: 19660953
54. Morton DJ, Stull TL (1999) Distribution of a family of Haemophilus influenzae genes containing CCAA nucleotide repeating units. FEMS Microbiol Lett 174: 303–309. PMID: 10339823
55. Hogg JS, Hu FZ, Janto B, Boissy R, Hayes J, Kneef R, et al. (2007) Characterization and modeling of the Haemophilus influenzae core- and supra-genomes based on the complete genomic sequences of Rd and 12 clinical nontypeable strains. Genome Biol 8: R103. PMID: 17550610